참고문헌
- Sikaroodi M, Galachiantz Y, Baranova A. Tumor markers: the potential of "omics" approach. Curr Mol Med 2010;10:249-257. https://doi.org/10.2174/156652410790963277
- Seregni E, Ferrari L, Martinetti A, Bombardieri E. Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin Surg Oncol 2001;20:147-166. https://doi.org/10.1002/ssu.1028
- Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007;18:175-184. https://doi.org/10.1016/j.ejim.2006.12.001
- Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856. https://doi.org/10.1038/nrc1739
- Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn 2009;3:597-605. https://doi.org/10.1517/17530050903266830
- Fan B, Xiong B. Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology 2011;58:239-245.
- Dilege E, Mihmanli M, Demir U, Ozer K, Bostanci O, Kaya C, et al. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. Hepatogastroenterology 2010;57:674-677.
- Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, et al. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 1997;17:2903-2906.
- Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33. https://doi.org/10.1007/s10120-013-0259-5
- Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions: where do we go? Dig Dis 2012;30:268-276. https://doi.org/10.1159/000336990
- Basbug M, Arikanoglu Z, Bulbuller N, Cetinkaya Z, Aygen E, Akbulut S, et al. Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepatogastroenterology 2011;58:400-405.
- Eskelinen M, Pasanen P, Kulju A, Janatuinen E, Miettinen P, Poikolainen E, et al. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res 1994;14:1427-1432.
- Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Colorectal Dis 2007;9:527-531. https://doi.org/10.1111/j.1463-1318.2007.01176.x
- Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, et al; NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012;23:1713-1722. https://doi.org/10.1093/annonc/mdr561
- Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005;93:740-743. https://doi.org/10.1038/sj.bjc.6602760
- Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, et al. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 1994;9:735-740. https://doi.org/10.1097/00006676-199411000-00011
- Chen S, Feng XY, Li YF, Zhao BW, Zhou ZW, Chen YB. The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy. J Surg Oncol 2013;107:641-645. https://doi.org/10.1002/jso.23300
- Park SS, Min JS, Lee KJ, Jin SH, Park S, Bang HY, et al. Risk stratification for serosal invasion using preoperative predictors in patients with advanced gastric cancer. J Gastric Cancer 2012;12:149-155. https://doi.org/10.5230/jgc.2012.12.3.149
- Kang Y, Wang F, Zu H, Yang Z, Xue Y. A new subclassification of pT4 gastric cancers according to the width of serosal invasion. PLoS One 2013;8:e68042. https://doi.org/10.1371/journal.pone.0068042
- Shim JH, Yoo HM, Lee HH, Kim JG, Jeon HM, Song KY, et al. Use of laparoscopy as an alternative to computed tomography (CT) and positron emission tomography (PET) scans for the detection of recurrence in patients with gastric cancer: a pilot study. Surg Endosc 2011;25:3338-3344. https://doi.org/10.1007/s00464-011-1722-1
- Hur H, Lee HH, Jung H, Song KY, Jeon HM, Park CH. Predicting factors of unexpected peritoneal seeding in locally advanced gastric cancer: indications for staging laparoscopy. J Surg Oncol 2010;102:753-757. https://doi.org/10.1002/jso.21685
피인용 문헌
- Preoperative Serum CEA and CA19-9 in Gastric Cancer - a Single Tertiary Hospital Study of 1,075 Cases vol.16, pp.7, 2014, https://doi.org/10.7314/apjcp.2015.16.7.2685
- Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer vol.16, pp.9, 2014, https://doi.org/10.7314/apjcp.2015.16.9.3867
- Classic tumor markers in gastric cancer. Current standards and limitations vol.88, pp.2, 2014, https://doi.org/10.15386/cjmed-409
- Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer vol.4, pp.3, 2016, https://doi.org/10.3892/mco.2015.712
- Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers vol.6, pp.1, 2014, https://doi.org/10.3390/biology6010016
- Stage Association of Preoperative Serum Carcinoembryonic Antigen with Gastric Adenocarcinoma in Iranian Patients vol.18, pp.10, 2017, https://doi.org/10.22034/apjcp.2017.18.10.2669
- Use of serum and peritoneal CEA and CA19-9 in prediction of peritoneal dissemination and survival of gastric adenocarcinoma patients: are they prognostic factors? vol.100, pp.4, 2014, https://doi.org/10.1308/rcsann.2018.0011
- Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites vol.19, pp.3, 2014, https://doi.org/10.5230/jgc.2019.19.e27
- Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale towards a Personalized Clinical Application vol.12, pp.6, 2014, https://doi.org/10.3390/cancers12061509